Can MS treatments protect the mind as well as the body?

NCT ID NCT01392872

Completed Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study follows people with relapsing-remitting multiple sclerosis who are starting immunosuppressant treatment. Researchers will track changes in cognitive abilities, fatigue, emotions, and overall quality of life over an extended period. The goal is to better understand how these treatments impact daily functioning beyond physical symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immunosuppressant treatment (as part of standard care) with neuropsychological assessments
What this could lead to: If successful, this could clarify how immunosuppressant treatments affect thinking, fatigue, and daily life in people with relapsing-remitting MS, helping guide more informed treatment decisions.
What could go wrong: This is a small observational study (48 participants) without a comparison group, so results may not apply broadly. It does not test a new drug, and findings may not change clinical practice directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.